Market News
Co-Diagnostics Sets 1-for-25 Reverse Split for Nasdaq Compliance

Key PointsCo-Diagnostics will execute its second reverse split of 2026 to stay above Nasdaq's…
View more
- Co-Diagnostics will execute its second reverse split of 2026 to stay above Nasdaq's minimum bid price.
- The 1-for-25 split cuts outstanding shares to roughly 521779 while preserving authorized capacity for future equity financings.
- Persistent losses and thin cash leave the company dependent on raising capital after the split takes effect.
Co-Diagnostics (CODX ), a molecular diagnostics company, announced on November 19, 2026, that it had filed an amendment to its articles of incorporation for a 1-for-25 reverse stock split. The action is intended to maintain compliance with Nasdaq’s $1.00 minimum bid-price requirement and preserve enough authorized shares for equity financings as needed.
The reverse split is scheduled to become effective at 12:01 a.m. Eastern time on November 24, 2026. Co-Diagnostics shares will continue to trade on the Nasdaq Capital Market under the CODX symbol and will begin trading on a split-adjusted basis when the market opens that day.
At the effective time, each 25 shares of issued and outstanding common stock will automatically combine into one fully paid, non-assessable share, with no change to par value. Based on 13,044,465 shares outstanding at the announcement, the company expects approximately 521,779 shares to be outstanding after the split. Total authorized capital stock will not change, leaving more room under the existing authorization for potential issuance as the outstanding count falls.
The numbers of shares available under equity incentive plans and issuable on outstanding options and warrants will also fall, with corresponding increases in option and warrant exercise prices under their existing terms. No fractional shares will be issued; fractional entitlements will be rounded up to the next whole share.
Shareholder Approval and Earlier Compliance Action
The shareholder vote on November 13, 2026 supplied the underlying authority. Shareholders approved one or more reverse splits at ratios of not less than 1-for-2, with the cumulative effect of all such splits not exceeding 1-for-750. The approval left the final ratio or ratios, timing and number of splits to the board for twelve months after the meeting, without another shareholder vote. The chosen action sits within that authorization.
This is the company’s second reverse-split action in 2026. The previous 1-for-30 consolidation was announced on December 30, 2025 and took effect on January 2, 2026, with the goal of regaining compliance with the same minimum bid-price requirement. Co-Diagnostics later said in a Nasdaq-compliance announcement that a March 9, 2026 notice confirmed it had regained compliance with all applicable continued-listing criteria, including the bid-price rule, and closed the earlier listing matter. Its shares resumed Nasdaq trading on March 11, 2026. The new announcement concerns maintaining compliance rather than regaining it.
Cash Position and Financing Capacity
The financing purpose comes alongside financial disclosures showing modest revenue, continuing losses and substantial operating cash use. The company’s third-quarter results put revenue at $0.3 million and the net loss at $6.3 million for the quarter ended September 30, 2026. Cash and cash equivalents totaled $0.7 million at quarter-end, while net cash used in operating activities was $20.7 million for the first nine months of 2026.
After quarter-end, the company completed a senior secured convertible debt financing with J.J. Astor & Co., providing approximately $2.1 million in initial funding before other transaction expenses. Up to an additional $1.0 million is available subject to specified conditions. That debt funding is separate from the potential equity issuance the reverse split is intended to facilitate.
The split changes the share structure, not the cash generation shown in those results. The open questions once the new structure takes effect are whether Co-Diagnostics can maintain Nasdaq’s bid-price compliance and whether the preserved share capacity will support additional equity funding.












